Drug intelligence / Profile preview

SBP-201

Development stage: Preclinical
Lead developer: SPARK Biopharma
Modality: Small Molecules
Administration: Subcutaneous, Intravenous, Oral

Overview

SBP-201 is a drug candidate developed by Sparkbiopharma Co., Ltd. for the treatment of neurodegenerative diseases, with a specific focus on Parkinson's disease. The drug's mechanism of action involves inducing the expression of antioxidant and anti-inflammatory genes, which are intended to protect brain cells and inhibit disease progression. It leverages Sparkbiopharma's proprietary "PhenoCure+" platform, which incorporates an AI-based molecular design technology known as "AI-TPU." This AI-TPU technology is designed to enhance protein stability and activity by inhibiting the binding between specific target proteins and E3 ubiquitin-protein ligases. SBP-201 is currently in the discovery phase of development.

Targets

CRL4-CRBN (Cereblon-based E3 ubiquitin ligase complex)

Beyond the preview

Go deeper on SBP-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBP-201.

Explore the full profile